ImaRx Tries Again

ImaRx Therapeutics Inc., a Tucson, Ariz.-based drug company using nanotech therapies for stroke and cancer, has filed for a $27.86 million IPO. It had filed for a $75 million public offering last year, but later withdrew it due to “unfavorable market conditions.” The company now plans to offer three million common shares at between $6.50 and $7.50 per share, and trade on the Nasdaq under ticker symbol IMRX. Maxim Group is serving as lead underwriter. Edison Moore Healthcare Ventures holds a 4.8% pre-IPO ownership position. www.imarx.com